DEVELOPING PRECISION THERAPIES FOR AUTOIMMUNE DIABETES

 

The recent U.S. market research has yielded promising insights, demonstrating a strong willingness among healthcare practitioners and payers to consider prescribing Diamyd® for type 1 diabetes.

image Ulf Hannelius
President and CEO, Diamyd Medical AB

ABOUT DIAMYD MEDICAL

Diamyd Medical develops precision medicine therapies for the prevention and treatment of autoimmune diabetes.

The investigational flagship product Diamyd® is a disease-modifying antigen-specific immunotherapy for the preservation of endogenous insulin production that has Orphan Drug Designation in the U.S. and has been granted Fast Track designation by the U.S. FDA. DIAGNODE-3, a confirmatory Phase III trial is actively recruiting patients with recent-onset Type 1 Diabetes in eight European countries and in the U.S.

Diamyd Medical’s shares are traded on Nasdaq First North Growth Market, ticker DMYD B.

 

ORGANISATION

Internal core competences constitute Diamyd Medical's core employees in collaboration with a global network of clinics, researchers and production units. Further expertise, including analysis- and laboratory services are contracted as needed during specific project phases. The model is based on long-term collaborations and cost efficiency.

Order GAD for preclinical research

GAD PRODUCTS